FEATURED CONTENT

• A Guide To Patient Engagement And Recruitment Solutions

  In this text we explore strategic solutions to patient recruitment and engagement challenges, emphasizing the importance of comprehensive patient engagement and recruitment strategies.

• Improving Rare Disease Recruitment With Data And AI

  Finding patients for rare disease clinical trials can be an uphill battle; fortunately, there are ways sponsors can address the most common stumbling blocks in the recruitment process.

• Pharma R&D Annual Review Supplement: New Active Substances

  Last year was by some distance the best year ever in terms of new active substances. Its total of 105 new debuts easily outstrips that of the previous record holder 2021’s 97. In 2025 we saw 97 new drugs, compared to the previous record of 84.

• Sol-Gel Builds Awareness Of Rare Skin Condition, Generates Leads

  Explore a 60-day HCP Awareness email campaign that surpassed industry benchmarks and generated a substantial number of leads.

• Sneak Peek Of Pharma R&D Annual Review

  Drug development experts remain intent on pharma’s prospects, especially in China, which have overtaken the US in first-time new drugs and continues to nurture a robust pipeline.

• Best Practices In Rare Disease Patient Recruitment

  Recruiting for rare disease clinical trials is daunting, and making patients aware of clinical trials, involving them in trial design, and building trust are a few ways sponsors can boost recruitment.

• SCOPE 2026 In The Rear-View Mirror

  Another SCOPE Summit is in the record books, and it was jam-packed with informative sessions. Themes included patient-centricity, AI (no surprise here), patient recruitment, and much more.

• Biopharma Reaping Numerous Benefits From AI

  Multiple AI use cases with significant impact have been identified, and they are expected to drive innovations in clinical trials, precision medicine, and commercial operations.

• Predictions For 2026 In Life Sciences

  Experts predict 2026 trends: more pragmatic trial design, expanded use of data and AI for patient matching, and registration and reporting of results for all human trials.

• Decision-Ready Data Restores Clinical Teams' Confidence

  The data underlying strategic decisions made by clinical teams often remain fragmented, backward-looking, or insufficiently validated. These teams need decision-ready data that brings clarity where it matters most.

• No More Swiss Holes: Filling The Gaps In Clinical Trial Disclosure

  This use case shows how sponsors can gain clarity on disclosure requirements when entering a new country.

• Busting Through Patient Recruitment Barriers

  Building patient trust fuels engagement, data and technology enable targeted recruitment, and real-time patient identification with consistent support drives scalable enrollment success.

• Clinical Trial Starts Rose At Slower Pace In 2024

  Clinical trial starts grew 5.5% to 10,503 in 2024, a slowdown from 2023’s 9.4% rise in trial starts. Sustained geopolitical and global regulatory pressures on pharma contributed to curbing momentum.

• Retention Begins With Recruiting The Right-Fit Patients

  Recruiting the right patients into a clinical trial is only half the battle. To combat attrition, sponsors must also institute measures that ensure patients remain comfortable and confident throughout the trial.

• 4 New Approvals In Q3 Across Gene, Cell, RNA Therapies

  Q3 2025 brought notable progress across the gene, cell, and RNA therapy landscape, marked by four new global approvals. While regulatory progress continued, clinical development activity slowed.

• The Complexities Of Effective Patient Retention In Clinical Trials

  Identifying and enrolling the right-fit patients from the outset is essential, but so is implementing comprehensive retention strategies that prioritize patient comfort, trust, and ongoing engagement.

• What Is ICH GCP, And How Does It Impact Clinical Planning?

  The updated ICH GCP guideline modernizes clinical trial standards, aligning with today’s technologies to enhance participant safety, data integrity, and risk-based trial design.

• Clinical Trial Disclosure Noncompliance: What Is Its Impact On Pharma M&As?

  Noncompliance with clinical trial disclosure regulations can jeopardize M&A deals. Understanding FDA and SEC requirements is critical to avoid red flags during due diligence.

• Challenges, Opportunities For Recruitment In The Digital Age

  Health literacy gaps and online misinformation hinder clinical trial recruitment. Meeting patients where they are — digitally and educationally — can improve engagement and enrollment success.

• The Healing Power Of Support Groups

  Support groups offer emotional strength and connection for patients and caregivers, helping them navigate medical challenges, treatment journeys, and the complexities of chronic conditions.